Tyrx has gained FDA clearance for a second-generation version of its AigisRx Antibacterial Envelope, designed to protect patients receiving pacemakers and other implantable heart devices from infection. The drug-device combination discharges two antibiotics within seven to 10 days and completely dissolves in the body in about 90 days, CEO Bob White said.

Full Story:

Related Summaries